RecruitingNot ApplicableNCT06033183

Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology


Sponsor

Neolys

Enrollment

100 participants

Start Date

Dec 2, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Analysis of the individual radiosensitivity in pediatric oncology


Eligibility

Min Age: 3 YearsMax Age: 18 Years

Inclusion Criteria6

  • Minor patient treated for a brain tumor, Ewing tumor, malignant mesenchymal tumor, neuroblastoma, nephroblastoma, Hodgkin's lymphoma treated with radiotherapy (+/- chemotherapy) for curative purposes.
  • Children or adolescents > 3 years old and < 18 years old
  • Patient with an indication for radiotherapy as part of the primary tumor local control strategy
  • Theoretical indication for radiotherapy in standard fractionation (1.8 Gy to 2.2 Gy / fraction: 5 fr/week) whatever the technique and the particle used
  • Patient affiliated with a social security scheme
  • Patient and/or parents or holders of parental authority having dated and signed an informed consent

Exclusion Criteria8

  • Patients with contraindications to blood sampling
  • Patients with contraindications to radiotherapy
  • Palliative radiotherapy
  • Patient with previous RT treatment in the same area (re-irradiation)
  • Patient with an indication of hypofractionated RT
  • Patient follow-up not possible
  • Persons deprived of liberty or under guardianship (including curatorship)
  • \-

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBlood sample

Blood sample collection : 2 X 5 ml


Locations(2)

Centre François Baclesse

Caen, France

Centre Oscar Lambret

Lille, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06033183


Related Trials